MovDisordV3, PascalFrancis, Corpus, bibRecord, 002C58

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

Identifieur interne : 002C58 ( PascalFrancis/Corpus ); précédent : 002C57; suivant : 002C59

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

Auteurs : J. H. Friedman ; S. A. Factor

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:00-0177296

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Psychose, Trouble psychiatrique, Lévodopa, Chimiothérapie, Antiparkinsonien, Olanzapine, Antagoniste sérotonine, Récepteur sérotoninergique, Clozapine, Neuroleptique, Psychotrope, Rispéridone, Antagoniste dopamine, Récepteur dopaminergique, Quétiapine, Traitement, Toxicité, Homme, Atypique, Antipsychotique, Thiéno benzodiazépine dérivé, Dibenzodiazépine.

English descriptors

KwdEn :
- Antiparkinson agent, Antipsychotic, Atypical, Chemotherapy, Clozapine, Dopamine antagonist, Dopamine receptor, Human, Levodopa, Mental disorder, Neuroleptic, Olanzapine, Parkinson disease, Psychosis, Psychotropic, Quetiapine, Risperidone, Serotonin antagonist, Serotonine receptor, Toxicity, Treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease`
A11	`01`	`1`		`@1 FRIEDMAN (J. H.)`
A11	`02`	`1`		`@1 FACTOR (S. A.)`
A14	`01`			`@1 Memorial Hospital of Rhode Island @2 Pawtucket, Rhode Island @3 USA`
A14	`02`			`@1 Parkinson's Disease and Movement Disorder Center of Albany Medical Center @2 Albany, New York @3 USA`
A20				`@1 201-211`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000082110890010`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 107 ref.`
A47	`01`	`1`		`@0 00-0177296`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Psychose @5 02`
C03	`02`	`X`	`ENG`	`@0 Psychosis @5 02`
C03	`02`	`X`	`SPA`	`@0 Psicosis @5 02`
C03	`03`	`X`	`FRE`	`@0 Trouble psychiatrique @5 03`
C03	`03`	`X`	`ENG`	`@0 Mental disorder @5 03`
C03	`03`	`X`	`SPA`	`@0 Trastorno psiquiátrico @5 03`
C03	`04`	`X`	`FRE`	`@0 Lévodopa @5 04`
C03	`04`	`X`	`ENG`	`@0 Levodopa @5 04`
C03	`04`	`X`	`SPA`	`@0 Levodopa @5 04`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`06`	`X`	`FRE`	`@0 Antiparkinsonien @5 06`
C03	`06`	`X`	`ENG`	`@0 Antiparkinson agent @5 06`
C03	`06`	`X`	`SPA`	`@0 Antiparkinsoniano @5 06`
C03	`07`	`X`	`FRE`	`@0 Olanzapine @2 NK @2 FR @5 07`
C03	`07`	`X`	`ENG`	`@0 Olanzapine @2 NK @2 FR @5 07`
C03	`07`	`X`	`SPA`	`@0 Olanzapina @2 NK @2 FR @5 07`
C03	`08`	`X`	`FRE`	`@0 Antagoniste sérotonine @5 08`
C03	`08`	`X`	`ENG`	`@0 Serotonin antagonist @5 08`
C03	`08`	`X`	`SPA`	`@0 Antagonista serotonina @5 08`
C03	`09`	`X`	`FRE`	`@0 Récepteur sérotoninergique @5 09`
C03	`09`	`X`	`ENG`	`@0 Serotonine receptor @5 09`
C03	`09`	`X`	`SPA`	`@0 Receptor serotoninérgico @5 09`
C03	`10`	`X`	`FRE`	`@0 Clozapine @2 NK @2 FR @5 10`
C03	`10`	`X`	`ENG`	`@0 Clozapine @2 NK @2 FR @5 10`
C03	`10`	`X`	`SPA`	`@0 Clozapina @2 NK @2 FR @5 10`
C03	`11`	`X`	`FRE`	`@0 Neuroleptique @5 11`
C03	`11`	`X`	`ENG`	`@0 Neuroleptic @5 11`
C03	`11`	`X`	`SPA`	`@0 Neuroléptico @5 11`
C03	`12`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 12`
C03	`12`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 12`
C03	`12`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 12`
C03	`13`	`X`	`FRE`	`@0 Rispéridone @2 NK @2 FR @5 13`
C03	`13`	`X`	`ENG`	`@0 Risperidone @2 NK @2 FR @5 13`
C03	`13`	`X`	`SPA`	`@0 Risperidona @2 NK @2 FR @5 13`
C03	`14`	`X`	`FRE`	`@0 Antagoniste dopamine @5 14`
C03	`14`	`X`	`ENG`	`@0 Dopamine antagonist @5 14`
C03	`14`	`X`	`SPA`	`@0 Antagonista dopamina @5 14`
C03	`15`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 15`
C03	`15`	`X`	`ENG`	`@0 Dopamine receptor @5 15`
C03	`15`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 15`
C03	`16`	`X`	`FRE`	`@0 Quétiapine @2 NK @2 FR @5 16`
C03	`16`	`X`	`ENG`	`@0 Quetiapine @2 NK @2 FR @5 16`
C03	`16`	`X`	`SPA`	`@0 Quetiapina @2 NK @2 FR @5 16`
C03	`17`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`17`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`17`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`18`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`18`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`18`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`19`	`X`	`FRE`	`@0 Homme @5 20`
C03	`19`	`X`	`ENG`	`@0 Human @5 20`
C03	`19`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`20`	`X`	`FRE`	`@0 Atypique @5 23`
C03	`20`	`X`	`ENG`	`@0 Atypical @5 23`
C03	`20`	`X`	`SPA`	`@0 Atípico @5 23`
C03	`21`	`X`	`FRE`	`@0 Antipsychotique @5 24`
C03	`21`	`X`	`ENG`	`@0 Antipsychotic @5 24`
C03	`21`	`X`	`SPA`	`@0 Antipsicótico @5 24`
C03	`22`	`X`	`FRE`	`@0 Thiéno benzodiazépine dérivé @4 INC @5 92`
C03	`23`	`X`	`FRE`	`@0 Dibenzodiazépine @4 INC @5 93`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 129`

Format Inist (serveur)

NO :	PASCAL 00-0177296 INIST
ET :	Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
AU :	FRIEDMAN (J. H.); FACTOR (S. A.)
AF :	Memorial Hospital of Rhode Island/Pawtucket, Rhode Island/Etats-Unis; Parkinson's Disease and Movement Disorder Center of Albany Medical Center/Albany, New York/Etats-Unis
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 2; Pp. 201-211; Bibl. 107 ref.
LA :	Anglais
CC :	002B02U01
FD :	Parkinson maladie; Psychose; Trouble psychiatrique; Lévodopa; Chimiothérapie; Antiparkinsonien; Olanzapine; Antagoniste sérotonine; Récepteur sérotoninergique; Clozapine; Neuroleptique; Psychotrope; Rispéridone; Antagoniste dopamine; Récepteur dopaminergique; Quétiapine; Traitement; Toxicité; Homme; Atypique; Antipsychotique; Thiéno benzodiazépine dérivé; Dibenzodiazépine
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Psychosis; Mental disorder; Levodopa; Chemotherapy; Antiparkinson agent; Olanzapine; Serotonin antagonist; Serotonine receptor; Clozapine; Neuroleptic; Psychotropic; Risperidone; Dopamine antagonist; Dopamine receptor; Quetiapine; Treatment; Toxicity; Human; Atypical; Antipsychotic
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Psicosis; Trastorno psiquiátrico; Levodopa; Quimioterapia; Antiparkinsoniano; Olanzapina; Antagonista serotonina; Receptor serotoninérgico; Clozapina; Neuroléptico; Psicotropo; Risperidona; Antagonista dopamina; Receptor dopaminérgico; Quetiapina; Tratamiento; Toxicidad; Hombre; Atípico; Antipsicótico
LO :	INIST-20953.354000082110890010
ID :	00-0177296

Links to Exploration step

Pascal:00-0177296

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease</title>
<author><name sortKey="Friedman, J H" sort="Friedman, J H" uniqKey="Friedman J" first="J. H." last="Friedman">J. H. Friedman</name>
<affiliation><inist:fA14 i1="01"><s1>Memorial Hospital of Rhode Island</s1>
<s2>Pawtucket, Rhode Island</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorder Center of Albany Medical Center</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S. A." last="Factor">S. A. Factor</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0177296</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0177296 INIST</idno>
<idno type="RBID">Pascal:00-0177296</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C58</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease</title>
<author><name sortKey="Friedman, J H" sort="Friedman, J H" uniqKey="Friedman J" first="J. H." last="Friedman">J. H. Friedman</name>
<affiliation><inist:fA14 i1="01"><s1>Memorial Hospital of Rhode Island</s1>
<s2>Pawtucket, Rhode Island</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Parkinson's Disease and Movement Disorder Center of Albany Medical Center</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S. A." last="Factor">S. A. Factor</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Antipsychotic</term>
<term>Atypical</term>
<term>Chemotherapy</term>
<term>Clozapine</term>
<term>Dopamine antagonist</term>
<term>Dopamine receptor</term>
<term>Human</term>
<term>Levodopa</term>
<term>Mental disorder</term>
<term>Neuroleptic</term>
<term>Olanzapine</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Psychotropic</term>
<term>Quetiapine</term>
<term>Risperidone</term>
<term>Serotonin antagonist</term>
<term>Serotonine receptor</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Psychose</term>
<term>Trouble psychiatrique</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Olanzapine</term>
<term>Antagoniste sérotonine</term>
<term>Récepteur sérotoninergique</term>
<term>Clozapine</term>
<term>Neuroleptique</term>
<term>Psychotrope</term>
<term>Rispéridone</term>
<term>Antagoniste dopamine</term>
<term>Récepteur dopaminergique</term>
<term>Quétiapine</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Homme</term>
<term>Atypique</term>
<term>Antipsychotique</term>
<term>Thiéno benzodiazépine dérivé</term>
<term>Dibenzodiazépine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FRIEDMAN (J. H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FACTOR (S. A.)</s1>
</fA11>
<fA14 i1="01"><s1>Memorial Hospital of Rhode Island</s1>
<s2>Pawtucket, Rhode Island</s2>
<s3>USA</s3>
</fA14>
<fA14 i1="02"><s1>Parkinson's Disease and Movement Disorder Center of Albany Medical Center</s1>
<s2>Albany, New York</s2>
<s3>USA</s3>
</fA14>
<fA20><s1>201-211</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000082110890010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>107 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0177296</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Psychose</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Trouble psychiatrique</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Mental disorder</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Trastorno psiquiátrico</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Olanzapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Olanzapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Olanzapina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Antagoniste sérotonine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Serotonin antagonist</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Antagonista serotonina</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Récepteur sérotoninergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Serotonine receptor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Receptor serotoninérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Clozapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Clozapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Clozapina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Rispéridone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Risperidone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Risperidona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>15</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>15</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>15</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Quétiapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Quetiapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Quetiapina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Atypique</s0>
<s5>23</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>Atypical</s0>
<s5>23</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Atípico</s0>
<s5>23</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>Antipsychotique</s0>
<s5>24</s5>
</fC03>
<fC03 i1="21" i2="X" l="ENG"><s0>Antipsychotic</s0>
<s5>24</s5>
</fC03>
<fC03 i1="21" i2="X" l="SPA"><s0>Antipsicótico</s0>
<s5>24</s5>
</fC03>
<fC03 i1="22" i2="X" l="FRE"><s0>Thiéno benzodiazépine dérivé</s0>
<s4>INC</s4>
<s5>92</s5>
</fC03>
<fC03 i1="23" i2="X" l="FRE"><s0>Dibenzodiazépine</s0>
<s4>INC</s4>
<s5>93</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>129</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0177296 INIST</NO>
<ET>Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease</ET>
<AU>FRIEDMAN (J. H.); FACTOR (S. A.)</AU>
<AF>Memorial Hospital of Rhode Island/Pawtucket, Rhode Island/Etats-Unis; Parkinson's Disease and Movement Disorder Center of Albany Medical Center/Albany, New York/Etats-Unis</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 2; Pp. 201-211; Bibl. 107 ref.</SO>
<LA>Anglais</LA>
<CC>002B02U01</CC>
<FD>Parkinson maladie; Psychose; Trouble psychiatrique; Lévodopa; Chimiothérapie; Antiparkinsonien; Olanzapine; Antagoniste sérotonine; Récepteur sérotoninergique; Clozapine; Neuroleptique; Psychotrope; Rispéridone; Antagoniste dopamine; Récepteur dopaminergique; Quétiapine; Traitement; Toxicité; Homme; Atypique; Antipsychotique; Thiéno benzodiazépine dérivé; Dibenzodiazépine</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Psychosis; Mental disorder; Levodopa; Chemotherapy; Antiparkinson agent; Olanzapine; Serotonin antagonist; Serotonine receptor; Clozapine; Neuroleptic; Psychotropic; Risperidone; Dopamine antagonist; Dopamine receptor; Quetiapine; Treatment; Toxicity; Human; Atypical; Antipsychotic</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Psicosis; Trastorno psiquiátrico; Levodopa; Quimioterapia; Antiparkinsoniano; Olanzapina; Antagonista serotonina; Receptor serotoninérgico; Clozapina; Neuroléptico; Psicotropo; Risperidona; Antagonista dopamina; Receptor dopaminérgico; Quetiapina; Tratamiento; Toxicidad; Hombre; Atípico; Antipsicótico</SD>
<LO>INIST-20953.354000082110890010</LO>
<ID>00-0177296</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C58 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002C58 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0177296
   |texte=   Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri